Discovery of neoepitope immunotherapeutic targets in diffuse pediatric high-grade gliomas
弥漫性儿童高级别胶质瘤中新表位免疫治疗靶点的发现
基本信息
- 批准号:10774404
- 负责人:
- 金额:$ 35.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-20 至 2024-09-19
- 项目状态:已结题
- 来源:
- 关键词:AccelerationBiologicalBiological AssayBrain NeoplasmsCancer PatientCause of DeathCell LineCell Surface ProteinsCentral Nervous System NeoplasmsCessation of lifeChildChildhoodChildhood Brain NeoplasmChildhood GliomaClinicalCombined Modality TherapyCommunitiesComputer AnalysisCoupledDataDiagnosisDiffuseDiseaseEpitopesEventExtracellular DomainFDA approvedGeneticGenetic TranscriptionGenomicsGenotype-Tissue Expression ProjectGliomaGoalsHealthHistologyImmunotherapeutic agentImmunotherapyInvestigationKnowledgeLabelMalignant Childhood NeoplasmMalignant NeoplasmsMissionModelingMolecularMutationNational Cancer InstituteNormal tissue morphologyPatientsPharmaceutical PreparationsPre-Clinical ModelPreclinical TestingProteinsPublic HealthRNA SplicingResearchResearch Project GrantsResistanceRoleScientific Advances and AccomplishmentsTestingTimeTranscriptTumor TissueUnited States National Institutes of HealthValidationVariantWorkcancer survivaldata visualizationdiffuse midline gliomaeffective therapyempowermentevidence baseextracellularglioma cell lineimprovedimproved outcomein vitro testingmolecular subtypesmolecular targeted therapiesneoantigensnew therapeutic targetnovelnovel strategiesnovel therapeutic interventionnovel therapeuticspatient retentionprecision medicineprogramsprotein aminoacid sequencetherapeutic targettherapeutically effectivetranscriptometumoruser-friendlyweb app
项目摘要
PROJECT SUMMARY
Pediatric cancer is the leading cause of disease-related death in children, yet very few drugs are specifically
labeled for pediatric malignancies, underscoring a need to identify novel molecular therapeutic targets to
improve outcomes for children with cancer, which is our long-term goal. Specifically, diffuse pediatric high-
grade gliomas (pHGGs) are resistant to multi-modal treatment and have had no new FDA-approved drugs in
the past 20 years, thus patients with these tumors are in urgent need of novel, effective therapeutic strategies.
Aberrant splicing contributes to neoepitope formation and represents a class of untapped targetable genetic
alterations that are largely unexplored in pHGG. Our central hypothesis of this research plan is that aberrant
splicing events can result in tumor-specific neoepitopes in pHGGs and these data can be rapidly harnessed
and prioritized for therapeutic targeting. The proposed work will test this hypothesis with two integrated specific
aims: 1) identify putative immunotherapeutic subtype-specific splice targets in pHGGs and 2) characterize
aberrant splice variation in pHGG preclinical models and validate immunotherapeutic splice targets for
preclinical testing. These studies will integrate transcriptional splice events with tumor tissue expression (PBTA
and Kids First X01), normal tissue expression (GTEx and available pediatric matched tissue normals), peptide
sequences (UniProt), and known extracellular domain annotations (UniProt) to identify and prioritize
neoepitopes generated in pHGGs. This work will elucidate novel splice-driven immunotherapeutic targets
through rigorous integrative computational analysis of splice variation in pHGG tumors, coupled with
orthogonal molecular assays, to validate presence and expression of these targets. The successful completion
of this project will generate significant new knowledge of aberrant splicing programs in pHGG and will identify
potential immunotherapeutic targets. This work is critical to understanding the genetic contributions of aberrant
splicing to pediatric cancer, will enable the research and clinical communities to rationally inform novel
immunotherapeutic strategies for pHGG, and will serve as a roadmap for investigation of neoepitopes in other
pediatric brain tumors. This work is highly relevant to the critical mission of the National Cancer Institute to
advance scientific knowledge and identify novel strategies to improve overall survival of cancer patients.
项目总结
儿童癌症是儿童疾病相关死亡的主要原因,但很少有药物是特效的。
标记为儿科恶性肿瘤,强调需要确定新的分子治疗靶点
改善癌症儿童的预后,这是我们的长期目标。具体地说,弥漫性儿科高-
级别胶质瘤(PHGGs)对多种模式的治疗具有抵抗力,并且在
在过去的20年里,这些肿瘤患者迫切需要新的、有效的治疗策略。
异常剪接有助于新表位的形成,代表了一类未开发的靶向基因
在PHGG中大部分未被勘探的蚀变。我们对这项研究计划的中心假设是
剪接事件可以在PHGG中产生肿瘤特异性新表位,这些数据可以快速利用
并优先用于治疗靶向。拟议的工作将用两个集成的具体实例来验证这一假设
目的:1)确定PHGGs中可能的免疫治疗亚型特异性剪接靶点;2)表征
PHGG临床前模型中的异常剪接变异和验证免疫治疗剪接靶点
临床前测试。这些研究将整合转录剪接事件和肿瘤组织表达(PBTA
和儿童第一个X01),正常组织表达(GTEx和可用的儿童匹配组织正常),肽
序列(UniProt)和已知的细胞外域注释(UniProt),以识别和区分优先顺序
在PHGGS中产生的新表位。这项工作将阐明新的剪接驱动的免疫治疗靶点
通过对PHGG肿瘤剪接变异的严格综合计算分析,
正交分子分析,以验证这些靶点的存在和表达。圆满完成
将在PHGG中产生关于异常剪接程序的重要新知识,并将识别
潜在的免疫治疗靶点。这项工作对于理解异常基因的遗传贡献至关重要。
拼接到儿科癌症,将使研究和临床界能够合理地告知新的
PHGG的免疫治疗策略,并将作为研究新表位的路线图
儿童脑瘤。这项工作与国家癌症研究所的关键使命高度相关
发展科学知识和确定新的战略,以提高癌症患者的总体存活率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jo Lynne Rokita其他文献
Jo Lynne Rokita的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Defining the biological boundaries to sustain extant life on Mars
定义维持火星现存生命的生物边界
- 批准号:
DP240102658 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Discovery Projects
Advanced Multiscale Biological Imaging using European Infrastructures
利用欧洲基础设施进行先进的多尺度生物成像
- 批准号:
EP/Y036654/1 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Research Grant
Open Access Block Award 2024 - Marine Biological Association
2024 年开放获取区块奖 - 海洋生物学协会
- 批准号:
EP/Z532538/1 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Research Grant
NSF/BIO-DFG: Biological Fe-S intermediates in the synthesis of nitrogenase metalloclusters
NSF/BIO-DFG:固氮酶金属簇合成中的生物 Fe-S 中间体
- 批准号:
2335999 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant
DESIGN: Driving Culture Change in a Federation of Biological Societies via Cohort-Based Early-Career Leaders
设计:通过基于队列的早期职业领袖推动生物协会联盟的文化变革
- 批准号:
2334679 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant
Collaborative Research: The Interplay of Water Condensation and Fungal Growth on Biological Surfaces
合作研究:水凝结与生物表面真菌生长的相互作用
- 批准号:
2401507 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant
REU Site: Modeling the Dynamics of Biological Systems
REU 网站:生物系统动力学建模
- 批准号:
2243955 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant
Collaborative Research: Conference: Large Language Models for Biological Discoveries (LLMs4Bio)
合作研究:会议:生物发现的大型语言模型 (LLMs4Bio)
- 批准号:
2411529 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant
Collaborative Research: Conference: Large Language Models for Biological Discoveries (LLMs4Bio)
合作研究:会议:生物发现的大型语言模型 (LLMs4Bio)
- 批准号:
2411530 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant
Collaborative Research: NSF-ANR MCB/PHY: Probing Heterogeneity of Biological Systems by Force Spectroscopy
合作研究:NSF-ANR MCB/PHY:通过力谱探测生物系统的异质性
- 批准号:
2412551 - 财政年份:2024
- 资助金额:
$ 35.6万 - 项目类别:
Standard Grant